Slingshot Insights | Tbph Overview

TBPH Overview

Upcoming Projects (TBPH)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (TBPH)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (TBPH)

Theravance (THRX) Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
Ticker: TBPH
Occurred on: Aug 23, 2021
Phase 3 data Evaluating Telavancin in Staphylococcus Aureus Bacteremia Expected Late 2017
Ticker: TBPH
Occurred on: Oct 09, 2017
Phase 2b Data Evaluating Velusetrag (TD-5108) in Gastroparesis Due Mid-2017
Ticker: TBPH
Occurred on: Aug 02, 2017
Phase 2a of TD-6450 for Hepatitis C virus due 2016
Ticker: TBPH
Occurred on: Jan 29, 2017
New Data for VIBATIV (telavancin) Reported in Presentations at IDWeek 2016
Ticker: TBPH
Occurred on: Nov 01, 2016
Phase 3 data of Revefenacin for COPD due fourth quarter 2016
Ticker: TBPH
Occurred on: Oct 20, 2016
Theravance Biopharma (TBPH) due to initiate phase 1 trial of IND candidate TD-1473 for treatment of ulcerative colitis in late 2016 - 2017
Ticker: TBPH
Occurred on: Oct 04, 2016
Theravance Biopharma (TBPH) Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis
Ticker: TBPH
Occurred on: Oct 04, 2016
Theravance Biopharma to Present New Data Highlighting Potent in vitro Activity of VIBATIV (telavancin) Against Difficult-to-Treat, Clinical Pathogens, Including MRSA, at ASM Microbe 2016 Conference
Ticker: TBPH
Occurred on: Jun 20, 2016
VIBATIV (Telavancin) Shows Greater In Vitro Potency Against Difficult-to-Treat Pathogens Causing Hospital-Acquired Bacterial Pneumonia, Including MRSA, Compared to Alternative Antibiotic Treatments
Ticker: TBPH
Occurred on: Apr 11, 2016
Theravance Releases Positive Results and Biomarker Data from Phase Phase 1 Study of TD-0714
Ticker: TBPH
Occurred on: Mar 09, 2016
Theravance Biopharma Announces Commercial Launch of VIBATIV(R) in Canada
Ticker: TBPH
Occurred on: Jan 26, 2016
Theravance Biopharma (TBPH) plans to initiate phase 1 study of IND candidate TD-1473 for treatment of ulcerative colitis in early 2016
Ticker: TBPH
Occurred on: Dec 10, 2015
Theravance Biopharma (TBPH) announces new development partner, Celgene (CELG), for its multivalent NS5A inhibitor TD-6450
Tickers: TBPH, CELG
Occurred on: Oct 28, 2015
Theravance Biopharma (TBPH) and Celgene (CELG) initiate Phase 2a clinical trial of TD-6450 to treat patients with Hepatitis C virus
Tickers: TBPH, CELG
Occurred on: Oct 28, 2015
Theravance Biopharma (TBPH) announces new developmental partnership with Celgene (CELG) for TD-6450, its multivalent NS5A inhibitor
Tickers: TBPH, CELG
Occurred on: Oct 28, 2015
Theravance Biopharma (TBPH) dilutes shares after UK value investor acquires 10%
Ticker: TBPH
Occurred on: Oct 26, 2015
Theravance Bio (TBPH) completes $55 million private capital raise
Ticker: TBPH
Occurred on: Oct 26, 2015

Strategic Initiatives (TBPH)

Don’t see a strategic initiative related to the company you care about? Create your own!